Product/Composition:- | Griseofulvin Tablets |
---|---|
Strength:- | 125 mg, 250 mg, 500 mg |
Form:- | Tablets |
Reference Brands:- | Grifulvin V(US); Griséofulvine(EU) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Griseofulvin inhibits fungal cell mitosis by disrupting microtubule formation, preventing fungal replication. It effectively treats dermatophyte skin, hair, and nail infections. Benefits include targeted oral therapy, good tissue penetration, and proven efficacy against dermatophytes, making it a reliable option for managing superficial fungal infections.
Griseofulvin tablets are approved in the EU and US for treating dermatophyte skin infections. In the EU, generic formulations are regulated by EMA, supported by dossiers demonstrating safety, efficacy, and manufacturing quality. In the US, FDA approval is based on comprehensive clinical data, with both branded and generic versions available. Both regions require detailed dossiers for approval and ongoing safety monitoring. For expert assistance with pharmaceutical dossiers, regulatory submissions, and compliance, visit PharmaTradz. We help facilitate smooth market access for griseofulvin tablets, ensuring adherence to European and American standards for effective treatment of dermatophyte infections.